Abdelnaser Elkhalili, MD
Rheumatology · Webster, TXNPI 1316935836
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 1,232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 1,232 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- AbbVie$3K
- UCB, Inc.$2K
- Johnson & Johnson$2K
- Pfizer$2K
- AstraZeneca$1K
- plus $8K from 36 others
Across 17 payments — averaging $10,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$155K
- Navidea Biopharmaceuticals, Inc.$18K
- GSK$8K
- E.r. Squibb & Sons, L.L.C.$30
What the payments were for
- Consulting fees$500%
- Food & beverage$22,11397%
- Education$5652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$22,729 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrenciaAbatacept/Maltose | 172 | $812,574 |
| RinvoqUpadacitinib | 47 | $492,651 |
| Orencia ClickjectAbatacept | 61 | $345,575 |
| Enbrel SureclickEtanercept | 28 | $221,960 |
| Cimzia (2 Pack)Certolizumab Pegol | 22 | $189,376 |
| Enbrel MiniEtanercept | 20 | $185,299 |
| ProliaDenosumab | 99 | $172,202 |
| Simponi AriaGolimumab | 21 | $162,909 |
| SimponiGolimumab | 27 | $162,459 |
| Xeljanz XrTofacitinib Citrate | 28 | $162,220 |
| Humira(Cf) PenAdalimumab | 23 | $158,569 |
| Taltz AutoinjectorIxekizumab | 21 | $143,172 |
| Cosentyx (2 Syringes)Secukinumab | 15 | $114,098 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 44 | $108,926 |
| ActemraTocilizumab | 29 | $103,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $944 | $878,639183 claims |
| AbbVieRinvoq | $3,354 | $492,65147 claims |
| AmgenProlia, Evenity (2 Syringes), Otezla | $4,952 | $337,171159 claims |
| Johnson & JohnsonSimponi Aria, Simponi | $1,688 | $325,36848 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,933 | $189,37622 claims |
| NovartisCosentyx (2 Syringes) | $968 | $114,09815 claims |
| Radius Health, Inc.Tymlos | $324 | $50,60617 claims |
| PfizerInflectra | $1,563 | $49,38811 claims |
| OrganonHadlima(Cf) | $77 | $11,22011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Webster
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.